Drug Utilization Review Board

Minutes Draft

Name of Meeting:	Drug Utilization Review Board
Date of Meeting:	December 12, 2019
Length of Meeting:	2 hours
Location of Meeting:	DMAS Board Room Floor 13

Members Present:
Chethan Bachireddy, MD, Chief Medical Officer, Chair
Rachel Cain, PharmD
Bill Rock, PharmD
Wendy Nash, PharmD
Melissa Chouinard, MD
Seth Brant, MD
Avtar Dhillon, MD
Michele Thomas, PharmD
Denese Gomes, NP
Kathryn Reid, PhD

Members Not Present:
Randy Ferrance, MD
Denise Lowe, PharmD

DMAS Attendees:
Donna Proffitt, RPh, Pharmacy Program Manager
Kurt Elward, MD, MPH
Andrew Ramsey, MD, MPH
Maryann McNeil, RPh, Pharmacist
Danielle Adeeb, CPhT, Pharmacy Contract Administrator

Contractors:
Debbie Moody, RPh, Pharmacist Account Executive, Magellan Health Services
Nancy Eldin, PharmD, Clinical Manager, Magellan Health Services
Jeni Hodzic, CPhT, Lead Formulary Analyst, Magellan Health Services

Visitors:
Beth Pegram, AveXis
Bethany Zanrucha, Sarepta
Brad Burmeister, Gilead
Brian Howell, AveXis
Bridget O'Connell, VCU Pharmacy Student

Christian Reyes, Optima Health
Dan Calloway, Sunovion
El-Sheba Okwei, VCU Pharmacy Student
Jennifer Greene, Genentech
John Stancil, Global Blood Therapeutics
Joseph Kupiec, VA Premier
Katherine Klem, Gilead
Kristie Bryerton, Sarepta
Melissa Miculis, Johnson & Johnson
Michael Craig, UCB
Mindy Conrad, Genentech
Nicholas Johnson, MD, MS-CI, VCU Health
Rebecca Bowers-Lanier, VHF
Rob Berringer, MCCVA
Stephanie Arnold, Paratek
Steve Patterson, Alkermes
Wendy Glenn, Genentech

Call to Order and Introductions

Dr. Chethan Bachireddy called the meeting to order at 2:08 pm.

Minutes – September 26, 2019

Meeting minutes were approved as submitted.

DUR Board Updates

Dr. Bachireddy welcomed and thanked everyone for attending the meeting and provided information about a change for today's meeting that includes having speakers for Zolgensma®.

RetroDUR Criteria Estimates

Dr. Nancy Eldin reviewed the Criteria Exception Estimates Reports with the DUR Board. The reports were broken down to the Top 40 Criteria Exception Estimates by Members and the Top 40 Criteria Exception Estimates by Total Payment Amount for Fee-For-Service (FFS) and each individual MCO plan.

Regarding the MCO reports, the individual MCO names have been replaced by a number to keep confidential. Dr. Cain stated that moving forward, all MCO reports will no longer include the individual MCO names.

Dr. Eldin noted criteria that appeared on ALL the Top 40 Criteria Exception Estimates Reports (FFS and MCOs). Dr. Eldin also reviewed the Criteria Exception Estimates Report for Lab Values with the DUR Board.

Dr. Eldin reviewed the Hemoglobin A1C Lab Value Over 9 and On Diabetic Meds for 6 Months Report. The DUR Board requested to see how many members are getting the hemoglobin A1C lab test done and the results are over 9 and make this number the denominator for the report. The DUR Board also requested to re-check these current members on the report in 6 months to see if they are getting better or if they continue to have hemoglobin A1C lab values over 9.

New Drugs

The DUR Board reviewed Inrebic® (fedratinib), Nourianz™ (istradefylline), Nubeqa® (darolutamide), Rozlytrek™ (entrectinib), Slynd™ (drospirenone), Temixys™ (lamivudine and tenofovir disoproxil fumarate), Trikafta™ (elexacaftor/tezacaftor/ivacaftor), Turalio™ (pexidartinib), Xenleta™ (lefamulin), and Xpovio™ (selinexor).

The DUR Board discussed the service authorization (SA) criteria and AutoPAs for the drugs in this section. A motion was made and approved to accept the service authorization criteria for Inrebic®, Nubeqa®, Rozlytrek™, Temixys™, Trikafta™, Xenleta™, and Xpovio™ as written. A motion was made and approved to have no service authorization criteria or AutoPA criteria for Turalio™. A motion was made and approved to have no AutoPA criteria for Xpovio™ and to accept the AutoPA criteria for Inrebic® and Nubeqa® as written.

For Rozlytrek™, a motion was made and approved to accept the AutoPA criteria as written with the addition of the AutoPA criteria only applying to 18 years of age and up. Members less than 18 years of age will need to meet the service authorization criteria for Rozlytrek™.

The DUR Board requested to run a utilization report for Cimduo® and Temixys™ in 6 months.

New Drugs: DUR Drugs with New Generics; DUR Drugs with New Dosage Forms/Strengths; Biosimilars; New PDL-Eligible Drugs and New Physician Administered Drugs

The DUR Board reviewed the new drugs in this section and had no questions.

Physician-Administered Drugs

The DUR Board reviewed Luxturna® (voretigene neparvovec-rzyl) and Zolgensma® (onasemnogene abeparvovec-xioi).

Speakers

- Brian Howell, Regional Medical Director, AveXis, Inc. (Zolgensma®)
- Kurt Elward, MD, MPH, DMAS (Zolgensma®)
- Nicholas Johnson, MD, MS-CI, VCU Health (Zolgensma®)

A motion was made and approved to accept the service authorization criteria for Zolgensma® as written. The DUR Board requested that DMAS bring back information in reference to the Centers of Excellence for Zolgensma®. For Luxturna®, a motion was made and approved to accept the service authorization criteria as written with the addition of requiring the physician be a specialist (Ophthalmologist with subspecialty in Retina).

A motion was made and approved for the below topics to be tabled for the next DUR meeting on March 12, 2020.

Specialty Drugs

- Crizanlizumab IV
- Semaglutide Oral
- MRx Pipeline

Topics for Discussion

- Concurrent Use of Opioids and Benzodiazepines
- SUPPORT Act Update
- DUR Quarterly Newsletter

Surveillance

- Opioid Use with Risk Factors and No Naloxone
- Opioid Use with Risk Factors and Getting Naloxone

Reports

- ProDUR
- RetroDUR
- Utilization Analysis Reports

Other Business

- ARTS Evaluation Update

The DUR Board meeting time will be changed to 1 pm - 4 pm for future meetings.

Next DUR Meetings

March 12, 2020
June 11, 2020
September 10, 2020
December 10, 2020

Meeting was adjourned at 4:08 pm.